LPA-CGR avocats assists Laboratoires DELBERT in raising funds
LPA-CGR avocats assists Laboratoires DELBERT in raising funds
14 september 2020
LPA-CGR avocats assists Laboratoires DELBERT in raising funds to finance the company’s external growth ambitions, simultaneously with the acquisition of Lepticur from SANOFI-AVENTIS.
A consortium of investors made up of Sagard NewGen, Socadif Capital Investissement, IDIA Capital Investissement and MACSF has reached an agreement with the management of Laboratoires DELBERT, which specialises in the acquisition and remarketing of medicines of major therapeutic interest (the “MMTIs”), particularly in infectiology, oncology and psychiatry, to take a minority stake and provide equity capital.
This contribution of €20m of equity is supplemented by unit-branch financing provided by BPIFrance and CIC Mezzanine, also for €20m, which will give the French laboratory, leader in its sector, the means to accelerate the pace of acquisition of new marketing authorisations as well as its internationalisation.
This fund raising was conducted simultaneously with the acquisition of Lepticur (a major anti-Parkinsonian drug) from SANOFI-AVENTIS.
LPA-CGR avocats advised Laboratoires DELBERT in the context of the entry of the consortium into its capital and the unit-branch financing, with a team led by Mathieu Selva-Roudon, partner and Noémie Attar, associate, on the tax aspects, as well as Raphaël Chantelot, partner, Thibault Willaume, counsel and Yvan Verité, associate, on the corporate aspects.
The other law firms advising on the transaction:
– Counsel to Sagard : Mc Dermott Will & Emery (Diana Hund, Maxime Fradet)
– Counsel to Socadif and IDIA: FieldFisher (Pascal Squercioni, Daniel Da Cruz Rodrigues)
– Counsel to BPIFrance: Eversheds (Sophie Perus, Sébastien Pontillo)
LPA-CGR avocats, with Raphaël Chantelot, corporate partner and Mathieu Selva-Roudon, tax partner, also advised Laboratoires DELBERT in the acquisition of Lepticur from SANOFI.
SANOFI was advised by Jones Day – Gaël Saint-Olive.